Fig. 1

Overall picture of cancer immunotherapy using gene-modified T cells. This figure shows two methods of developing gene-modified T cells: one is based on the use of tumor antigen-specific TCRs from tumor-specific T cells or their clones which recognize the complex of MHC class I molecule and TAA-derived peptide, and the other is based on the use of CAR